Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL388 Target Snapshot

MT4 · CELL-LINE · Homo sapiens

12,476Compounds
1,662Assays
39Approved Drugs
3,946.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats MT4 as ChEMBL target CHEMBL388. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
MT4
CELL-LINE · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL388
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether MT4 still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelMT4
UniProt AccessionN/A

MT4

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as MT4.

Review nameMT4
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

39
Approved
8
Phase III
10
Phase II
Assay Mix

Activity Type Distribution

IC501,665.0
KI2.0
EC502,279.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL314298 10.8 IC50 0.016 Preclinical
CHEMBL83462 10.1 IC50 0.08 Preclinical
CHEMBL314758 9.82 IC50 0.15 Preclinical
CHEMBL206031 9.66 IC50 0.22 Clinical
CHEMBL71728 9.52 EC50 0.3 Preclinical
CHEMBL172850 9.4 EC50 0.4 Preclinical
CHEMBL70442 9.4 EC50 0.4 Preclinical
CHEMBL70517 9.4 EC50 0.4 Preclinical
CHEMBL176930 9.32 EC50 0.48 Preclinical
CHEMBL414640 9.24 EC50 0.57 Preclinical
Distribution

pChEMBL Value Distribution

297
5.0
309
5.5
304
6.0
264
6.5
294
7.0
174
7.5
150
8.0
73
8.5
44
9.0
3
9.5
pChEMBL
Approved Drugs

Approved Drugs

ELVITEGRAVIR
CHEMBL204656
Approved 2012
PLERIXAFOR
CHEMBL18442
Approved 2008
ETRAVIRINE
CHEMBL308954
Approved 2008
DARUNAVIR
CHEMBL1323
Approved 2006
ATAZANAVIR
CHEMBL1163
Approved 2003
ADEFOVIR DIPIVOXIL
CHEMBL922
Approved 2002
LOPINAVIR
CHEMBL729
Approved 2000
AMPRENAVIR
CHEMBL116
Approved 1999
EFAVIRENZ
CHEMBL223228
Approved 1998
DELAVIRDINE MESYLATE
CHEMBL929
Approved 1997
DELAVIRDINE
CHEMBL593
Approved 1997
NELFINAVIR
CHEMBL584
Approved 1997
RITONAVIR
CHEMBL163
Approved 1996
NEVIRAPINE
CHEMBL57
Approved 1996
SAQUINAVIR
CHEMBL114
Approved 1995
LAMIVUDINE
CHEMBL141
Approved 1995
STAVUDINE
CHEMBL991
Approved 1994
ZALCITABINE
CHEMBL853
Approved 1992
ZIDOVUDINE
CHEMBL129
Approved 1987
ETOPOSIDE
CHEMBL44657
Approved 1983
DOXORUBICIN
CHEMBL53463
Approved 1974
DACTINOMYCIN
CHEMBL1554
Approved 1964
MERCAPTOPURINE ANHYDROUS
CHEMBL1425
Approved 1953
Assay Landscape

Assay Landscape

1,669
Total Assays
1,532
Tested Compounds
3
Assay Types
Functional — 1,154 assays, 1,532 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1,153 1,532 6.3
organism-based format 1 0
ADME — 451 assays, 115 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 451 115 4.8
Toxicity — 64 assays, 13 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 64 13 5.2

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine